Scientific Agenda

Thursday, February 10, 2011

Session IA: Oncology Symptom Management Workshop
(Parallel to Session IB: NOCR Multiple Myeloma Workshop)
Chair: Charles L. Loprinzi, MD

4:30 pm	Welcome
4:40 pm	Managing gastrointestinal toxicity – mucositis, nausea, diarrhea Axel Grothey, MD
5:00 pm	Dermatologic adverse events in the era of targeted therapies Mario E. Lacouture, MD
5:20 pm	Cardiac toxicity of targeted agents Jean-Bernard Durand, MD
5:40 pm	Pulmonary toxicity – prevention, causation, and management Ramaswamy Govindan, MD
6:00 pm	Pain and cancer – tumor related and treatment related Sandra E. Kurtin, RN, AOCN, ANP-C
6:20 pm	Neurologic toxicity of chemotherapeutic and targeted agents Charles L. Loprinzi, MD
6:40 pm	Clinical case panel review and Q&A Moderator: Charles L. Loprinzi, MD
7:00 pm	Conclusion
7:15 pm	Adjourn

Session IB : NOCR Multiple Myeloma Workshop
(Parallel to Session IA: Oncology Symptom Management Workshop)
Chair: Robert Z. Orlowski, MD, PhD

4:30 pm	Welcome
4:40 pm	Diagnosis, staging, evaluation and risk assessment Joseph R. Mikhael, MD, MEd, FRCPC
5:05 pm	Induction therapy of SCT-eligible patients Rafael Fonseca, MD
5:30 pm	Frontline therapy for non-transplant patients – treatment decision making based on clinical and biologic factors Antonio Palumbo, MD
5:55 pm	First relapse – making the hard choices easier Robert Z. Orlowski, MD, PhD
6:20 pm	Employing the old and the new in third line and beyond Rafael Fonseca, MD
6:45 pm	Panel Discussion: Managing patients with significant co-morbidities and complications of Myeloma therapy Moderator: Robert Z. Orlowski, MD, PhD
7:05 pm	Conclusion
7:15 pm	Adjourn

Friday, February 11, 2011

7:00 am	Breakfast
8:00 am	Welcome and introduction James Epstein, MD

Session II: B-Cell Malignancies: Managing Patients not Responding to or Relapsing from Frontline Therapy
Chair: Morton Coleman, MD

8:10 am	Pre-activity ARS
8:15 am	Chronic lymphocytic leukemia Alessandra Ferrajoli, MD
8:35 am	Follicular lymphoma Morton Coleman, MD
8:55 am	Aggressive lymphomas Myron S. Czuczman, MD
9:15 am	Clinical case panel review and Q&A
9:30 am	Conclusion
9:40 am	Break

Session III: Genitourinary Oncology
Chair: Robert Dreicer, MD, FACP

10:00 am	Pre-activity ARS
10:05 am	Emerging therapeutic strategies for CRPC Charles J. Ryan, MD
10:25 am	Urothelial cancers – is there progress? Robert Dreicer, MD, FACP
10:45 am	Renal cell carcinoma – optimally managing your patient Walter Stadler, MD FACP
11:05 am	Panel discussion Moderator: Robert Dreicer, MD, FACP
11:30 am	Lunch

Session IV: Gastrointestinal Oncology – Clinical Updates and Emerging Data

1:00 pm	Pre-activity ARS
1:10 pm	Biomarkers and CRC – what do we know for sure? J. Randolph Hecht, MD
1:35 pm	Hepatobiliary-pancreatic cancers Alan P. Venook, MD
2:00 pm	UGI cancers – what have we learned from recent trials? David H. Ilson, MD, PhD
2:25 pm	Clinical case panel review and Q&A

Session VA: Hematological Malignancies
(Parallel with Session VB: Uncommon Malignancies I)

3:00 pm	Pre-activity ARS
3:10 pm	CML – long term management strategies from M.D. Anderson Jerald Radich, MD
3:35 pm	MPN – what is the long term prognosis for JAK2 inhibitors? Animesh Pardanani, MD
4:00 pm	MDS – prognostic scoring and therapeutic choices Jerald Radich, MD
4:25 pm	Conclusion
4:35 pm	Adjourn
5:30 pm – 7:00 pm	Evening networking reception

Session VB: Uncommon Malignancies I
(Parallel with Session VA: Hematological Malignancies)

3:00 pm	Pre-activity ARS
3:10 pm	Neuroendocrine Tumors Alan P. Venook, MD
3:35 pm	Progress in malignant melanoma Keith T. Flaherty, MD
4:00 pm	Extra-nodal lymphomas Myron S. Czuczman, MD
4:25 pm	Conclusion
4:35 pm	Adjourn
5:30 pm – 7:00 pm	Evening networking reception

Saturday, February 12, 2011

7:00 am	Breakfast
8:00 am	Welcome Christy A. Russell, MD

Session VI: Women’s Cancers: Updates in Gynecological and Breast Malignancies
Chairs: Bradley J. Monk, MD, FACOG, FACS and Christy A. Russell, MD

8:10 am	Pre-activity ARS
8:20 am	Hormone receptor positive breast cancer Christy A. Russell, MD
8:40 am	HER2 positive breast cancer Susana Campos, MD, MPh
9:00 am	Triple negative breast cancer Ruth M. O’Regan, MD
9:20 am	Clinical case panel review and Q&A
9:40 am	Ovarian cancer Bradley J. Monk, MD, FACOG, FACS
10:00 am	Cervical cancer Susana Campos, MD, MPh
10:20 am	Endometrial cancer Bradley J. Monk, MD, FACOG, FACS
10:40 am	Conclusion
11:00 am	Break

Session VII: Lung Cancer
Chair: Corey J. Langer, MD, FACP

11:15 am	Pre-activity ARS
11:20 am	Clinical, histologic and biologic markers - their role in therapeutic decision making Ramaswamy Govindan, MD
11:40 am	Advanced NSCLC-novel targets and novel agents Anne S. Tsao, MD
12:05 pm	Panel discussion: Decision tree for advanced NSCLC Moderator: Corey J. Langer, MD, FACP
12:20 pm	Conclusion
12:30 pm	Lunch

Session VIIIA: Uncommon Malignancies II
(Parallel with Session VIIIB: Uncommon Malignancies III)

2:00 pm	Pre-activity ARS
2:05 pm	Uncommon breast tumors Ruth M. O’Regan, MD
2:30 pm	Uncommon thoracic cancers Anne S. Tsao, MD
2:55 pm	Uncommon GU malignancies Charles J. Ryan, MD
3:20 pm	Conclusion
3:30 pm	Adjourn

Session VIIIB: Uncommon Malignancies III
(Parallel with Session VIIIA: Uncommon Malignancies II)

2:00 pm	Pre-activity ARS
2:05 pm	Thyroid cancers Corey J. Langer, MD, FACP
2:30 pm	GIST J. Randolph Hecht, MD
2:55 pm	Impact of HPV on the field of Head and Neck Cancers Corey J. Langer, MD, FACP
3:20 pm	Conclusion
3:30 pm	Adjourn